Annual Review of Systemic Medical Treatment for Colorectal Cancer in 2025

IF 2
Zengzhi Cai, Fan Chen, Ying Jin, Feng Wang
{"title":"Annual Review of Systemic Medical Treatment for Colorectal Cancer in 2025","authors":"Zengzhi Cai,&nbsp;Fan Chen,&nbsp;Ying Jin,&nbsp;Feng Wang","doi":"10.1002/cai2.70057","DOIUrl":null,"url":null,"abstract":"<p>This review summarizes landmark advances in colorectal cancer treatment in 2025, characterizing the transition to dynamic precision oncology. Immunotherapy has revolutionized mismatch repair-deficient or microsatellite instability-high patients, becoming the standard first-line and perioperative regimen. Precision medicine expanded to patients with BRAF V600E, KRAS mutation, and HER2 amplification. While circulating tumor DNA utility was confirmed for surveillance and guiding rechallenge, its role in real-time treatment adjustment continues to be explored.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 2","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13066762/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Innovation","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cai2.70057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

This review summarizes landmark advances in colorectal cancer treatment in 2025, characterizing the transition to dynamic precision oncology. Immunotherapy has revolutionized mismatch repair-deficient or microsatellite instability-high patients, becoming the standard first-line and perioperative regimen. Precision medicine expanded to patients with BRAF V600E, KRAS mutation, and HER2 amplification. While circulating tumor DNA utility was confirmed for surveillance and guiding rechallenge, its role in real-time treatment adjustment continues to be explored.

2025年结直肠癌全身药物治疗年度回顾。
本文综述了2025年结直肠癌治疗的里程碑式进展,其特点是向动态精确肿瘤学过渡。免疫治疗彻底改变了错配修复缺陷或微卫星不稳定性高的患者,成为标准的一线和围手术期治疗方案。精准医疗扩展到BRAF V600E、KRAS突变和HER2扩增的患者。虽然循环肿瘤DNA的效用已被证实用于监测和指导再挑战,但其在实时治疗调整中的作用仍在继续探索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书